Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats

Xenobiotica

Volumn 41, Issue 9, 2011, Pages 797-804

  Lee, Joo Hyun ^a   Oh, Ju Hee ^a   Lee, Young Joo ^a  

^a Kyung Hee University   (South Korea)

Author keywords

Docetaxel; hyperlipidaemia; pharmacokinetics; rats

Indexed keywords

DOCETAXEL; POLOXAMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; HYPERLIPIDEMIA; LIVER METABOLISM; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CHROMATOGRAPHY, LIQUID; HYPERLIPIDEMIAS; INJECTIONS, INTRAVENOUS; MALE; MASS SPECTROMETRY; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; TAXOIDS; TIME FACTORS;

RATTUS;

EID: 79961181857     PISSN: 00498254     EISSN: 13665928     Source Type: Journal    
DOI: 10.3109/00498254.2011.580019     Document Type: Article

References (40)

1. Agnoli C, Berrino F, Abagnato CA, Muti P, Panico S, Crosignani P, Krogh V. (2010).Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: A nested case-control study. Nutr Metab Cardiovasc Dis 20:41-48.
2. Baker SD, Sparreboom A, Verweij J. (2006).Clinical pharmacokinetics f docetaxel: Recent developments. Clin Pharmacokinet 45:235-252. (Pubitemid 43327491)
3. Barr J, Chamouard JM, Houin G, Tillement JP. (1985).Equilibrium dialysis, ultrafiltration, and ultracentrifugation compared for determining the plasma-protein-binding characteristics of valproic acid. Clin Chem 31:60-64. (Pubitemid 15079346)
4. Blonder JM, Baird L, Fulfs JC, Rosenthal GJ. (1999).Dose-dependent hyperlipidemia in rabbits following administration of poloxamer 407 gel. Life Sci 65:PL261-PL266.
5. Brocks DR, Ala S, Aliabadi HM. (2006).The effect of increased lipoprotein levels on the pharmacokinetics of cyclosporine A in the laboratory rat. Biopharm Drug Dispos 27:7-16. (Pubitemid 43173969)
6. Chiou WL. (1978).Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma evel-time curve. J Pharmacokinet Biopharm 6:539-546.
7. Choi YH, Suh JH, Lee JH, Cho IH, Lee MG. (2010).Effects of tesmilifene, a substrate of CYP3A and an inhibitor of P-glycoprotein, on the pharmacokinetics of intravenous and oral docetaxel in rats. J Pharm Pharmacol 62:1084-1088.
8. Crommentuyn KM, Schellens JH, van den Berg JD, Beijnen JH. (1998).In-vitro metabolism of anti-cancer drugs, methods and applications: Paclitaxel, docetaxel, tamoxifen and ifosfamide. Cancer Treat Rev 24:345-366. (Pubitemid 28537770)
9. Eliot LA, Foster RT, Jamali F. (1999).Effects of hyperlipidemia on the pharmacokinetics of nifedipine in the rat. Pharm Res 16:309-313. (Pubitemid 29135138)
10. Fukushima K, Shibata M, Mizuhara K, Aoyama H, Uchisako R, Kobuchi S, Sugioka N, Takada K. (2009).Effect of serum lipids on the pharmacokinetics of atazanavir in hyperlipidemic rats. Biomed Pharmacother 63:635-642.
11. Gibaldi M, Perrier D. (1982).Pharmacokinetics. 2nd ed. New York, USA: Marcel-Dekker.
12. Gilbert DC, Parker C. (2005).Docetaxel for the treatment of prostate cancer. Future Oncol 1:307-314.
13. Hammarsten J, H?stedt B. (2004).Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer. Blood Press 13:47-55. (Pubitemid 38455847)
14. Johnston TP, Baker JC, Jamal AS, Hall D, Emeson EE, Palmer WK. (1999).Potential downregulation of HMG-CoA reductase after prolonged administration of P-407 in C57BL/6 mice. J Cardiovasc Pharmacol 34:831-842.
15. Johnston TP, Nguyen LB, Chu WA, Shefer S. (2001).Potency of select statin drugs in a new mouse model of hyperlipidemia and atherosclerosis. Int J Pharm 229:75-86. (Pubitemid 32972083)
16. Johnston TP, Palmer WK. (1993).Mechanism of poloxamer 407- induced hypertriglyceridemia in the rat. Biochem Pharmacol 46:1037-1042. (Pubitemid 23280545)
17. Kabanov AV, Batrakova EV, Alakhov VY. (2002).Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 54:759-779. (Pubitemid 35247525)
18. Kabanov AV, Batrakova EV, Miller DW. (2003).Pluronic block copolymers as modulators of drug efflux transporter activity in the blood-brain barrier. Adv Drug Deliv Rev 55:151-164. (Pubitemid 36078456)
19. Lee JH, Lee MG. (2008).Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin. Pharm Res 25:1915-1924.
20. Lee MG, Chiou WL. (1983).Evaluation of potential causes for the incomplete bioavailability of furosemide: Gastric first-pass metabolism. J Pharmacokinet Biopharm 11:623-640. (Pubitemid 14070321)
21. LOWRY OH, ROSEBROUGH NJ, FARR AL, RANDALL RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
22. Luke DR. (1992).Immunosuppressive effect of cyclosporine in the hyperlipidemic rat model. Biopharm Drug Dispos 13:635-645.
23. Lyseng-Williamson KA, Fenton C. (2005).Docetaxel: A review of its use in metastatic breast cancer. Drugs 65:2513-2531. (Pubitemid 41697318)
24. Marre F, Sanderink GJ, de Sousa G, Gaillard C, Martinet M, Rahmani R. (1996).Hepatic biotransformation of docetaxel (Taxotere) in vitro: Involvement of the CYP3A subfamily in humans. Cancer Res 56:1296-1302. (Pubitemid 26080972)
25. McEntee M, Silverman JA, Rassnick K, Zgola M, Chan AO, Tau PT, Page RL. (2003).Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats. Vet Comp Oncol 1:105-112.
26. Mu CF, Balakrishnan P, Cui FD, Yin YM, Lee YB, Choi HG, Yong CS, Chung SJ, Shim CK, Kim DD. (2010).The effects of mixed MPEG-PLA/Pluronic copolymer micelles on the bioavailability and multidrug resistance of docetaxel. Biomaterials 31:2371-2379.
27. Nemunaitis J, Deeg HJ, Yee GC. (1986).High cyclosporin levels after bone marrow transplantation associated with hypertriglyceridaemia. Lancet 2:744-745. (Pubitemid 16022229)
28. Palmer WK, Emeson EE, Johnston TP. (1998).Poloxamer 407- induced atherogenesis in the C57BL/6 mouse. Atherosclerosis 136:115-123. (Pubitemid 28341448)
29. Porter CJ, Caliph SM, Charman WN. (1997).Differences in pre- and post-prandial plasma lipid profiles affect the extraction efficiency of a model highly lipophilic drug from beagle dog plasma. J Pharm Biomed Anal 16:175-180. (Pubitemid 27462701)
30. Saloustros E, Georgoulias V. (2008).Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev Anticancer Ther 8:1207-1222.
31. Shayeganpour A, Jun AS, Brocks DR. (2005).Pharmacokinetics of amiodarone in hyperlipidemic and simulated high fat-meal rat models. Biopharm Drug Dispos 26:249-257. (Pubitemid 41341825)
32. Shayeganpour A, Korashy H, Patel JP, El-Kadi AO, Brocks DR. (2008). The impact of experimental hyperlipidemia on the distribution and metabolism of amiodarone in rat. Int J Pharm 361: 78-86.
33. Shirakawa K, Takara K, Tanigawara Y, Aoyama N, Kasuga M, Komada F, Sakaeda T, Okumura K. (1999).Interaction of docetaxel ("Taxotere") with human P-glycoprotein. Jpn J Cancer Res 90:1380-1386. (Pubitemid 30032078)
34. Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. (1998). Preclinical pharmacokinetics of paclitaxel and docetaxel. Anticancer Drugs 9:1-17. (Pubitemid 28088174)
35. Urien S, Barr J, Morin C, Paccaly A, Montay G, Tillement JP. (1996). Docetaxel serum protein binding with high affinity to α1-acid glycoprotein. Invest New Drugs 14:147-151. (Pubitemid 26340683)
36. van Waterschoot RA, Lagas JS, Wagenaar E, van der Kruijssen CM, van Herwaarden AE, Song JY, Rooswinkel RW, van Tellingen O, Rosing H, Beijnen JH, Schinkel AH. (2009).Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res 69:8996-9002.
37. Wilkinson GR, Shand DG. (1975).Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 18:377-390.
38. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. (1998).Prediction of coronary heart disease using risk factor categories. Circulation 97:1837-1847. (Pubitemid 28213628)
39. Wout ZG, Pec EA, Maggiore JA, Williams RH, Palicharla P, Johnston TP. (1992).Poloxamer 407-mediated changes in plasma cholesterol and triglycerides following intraperitoneal injection to rats. J Parenter Sci Technol 46:192-200. (Pubitemid 23052584)
40. Yan YD, Kim DH, Sung JH, Yong CS, Choi HG. (2010).Enhanced oral bioavailability of docetaxel in rats by four consecutive days of pretreatment with curcumin. Int J Pharm 399:116-120.